Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RELIEF THERAPEUTICS’ WHOLLY OWNED SUBSIDIARY, APR APPLIED PHARMA RESEARCH, REPORTS POSITIVE INTERIM DATA FROM ITS CLINICAL TRIAL OF NOVEL NASAL SPRAY SENTINOX IN SARS-COV-2 INFECTED PATIENTS
Ad Hoc Announcement pursuant to Art. 53 LR,
27 October 2021
Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients
Results Confirm the Safety and Tolerability of Sentinox and Suggest It Could Be Effective in Reducing Time to Negativization in SARS-CoV-2 Infected Patients
Geneva, Switzerland, October 27, 2021 –
RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that its wholly owned subsidiary, APR Applied Pharma Research SA (“APR”), reported positive interim results from its clinical trial of nasal spray Sentinox in SARS-CoV-2 infected patients, confirming its safety and tolerability. Relief also reported that data from the study suggest that Sentinox could be effective in reducing the SARS-CoV-2 viral load at the level of the nasal mucosa.
The post-market, confirmatory, interventional, randomized, placebo controlled clinical study is expected to enroll a total of 57 patients. The study is designed to assess the efficacy and safety of Sentinox spray in reducing viral load in the upper respiratory airways of recently infected SARS-CoV-2 individuals and is being conducted by the Hygiene Unit of IRCCS Policlinico San Martino Hospital in Genoa, Italy and coordinated by Prof. Giancarlo Icardi as lead investigator.
The interim analysis, based on 30 patients who have completed the study -- 10 patients for each treatment group (0.5 ml into each nostril, 3x/day, 5x/day or control group, for five days) -- showed that all patients treated with Sentinox tested negative for SARS-CoV-2 by the end of the study period (Day 21). By contrast, one out of 10 patients in the control group was still positive by Day 21. All subjects using Sentinox 3 times a day had already tested negative by visit number 7 (V7; Day 10) vs. 70% of subjects in the control group over the same study period. At visit 4, 5 and 6, a trend in favor of the 3 times a day treated group vs. control group was observed (10% of patients using Sentinox tested negative at V4 vs 0% of patients in the control arm; 40% of patients using Sentinox tested negative vs 20% in the control arm at V5; 70% of patients using Sentinox tested negative vs 40% at V6). For the purpose of this study, subjects are considered negative when their COVID-19 test becomes negative and remains negative throughout the study period.
Prof. Giancarlo Icardi, head of the Hygiene Unit of IRCCS Policlinico San Martino Hospital in Genoa and lead investigator, commented, “The interim analysis results are encouraging. Indeed, the preliminary efficacy data suggest that using Sentinox, in addition to standard of care, could accelerate the time to a negative SARS-CoV-2 test result, thereby allowing patients to resume their normal daily activities sooner. By lowering the viral load in the nasal mucosa, the use of Sentinox could help reduce the transmissibility of the virus and, consequentially, its spread. Moreover, it is possible that, by including a larger number of patients and clinical parameters, Sentinox will prove to be a helpful tool for improving clinical outcomes in patients with mild COVID-19 in addition to standard of care. In general, we expect that the positive data obtained so far will be confirmed by the end of the study.”
Raghuram (Ram) Selvaraju, Chairman of the Board of Relief added, “These positive preliminary results serve to further illustrate the versatility of APR’s proprietary, globally patented Tehclo® nanotechnology platform. We are very encouraged by the data and remain committed to proactively progressing this program with the hope that we can eventually bring Sentinox to market as an important, additional, protective option for the treatment and spread of COVID-19.”
Large blocks today.
Lakota thank you for always providing a solid and positive perspective. Your exactly correct re: fear.
3bb
Good morning Pete….thank you for the perspective. We sit and wait. The best to you….
Thanks JT…Yes…suddle but none the less selling pressure
Hmmmm odd
What’s the significance of all of the 867 sell blocks? Too many to count…
Any thoughts on the heavy sell spike at days end?
Good gracious...push on over to the .38 and buy it up. Quit dinging around with .3727.
Please provide link to support your statement that AITX "just" won Homeland Security award.
This is bullsh*t! I just don’t get peoples societal tendency to do crap like that. Hopefully some of the nrx uptick will flow on over to rvvtf.
Ditto!
Complete sh*t with this one!
Major accumulation happening.
Ditto!
Agree…we’ll written Penny!
Any speculation on where RLFTF pps goes from here? NRXP is clearly on the rise. If we don’t get to participate in the visibility … frustrating.
Good morning. NRX up over $4 in morning pre market. Hopefully it’ll trickle over to us….RLFTF. ??
Wow…eye opening! Thank you for sharing.
They’ve come out swinging.
Thank Dane….appreciate you.
Thanks for clarifying!
Thanks for the info Tbear
Went up that amount or went to that amount?
Would’ve been nice to have pushed through the .40 barrier. Next week!!
Agree 100% with you Penny.
This is fabulous news!
Good morning!
What’s up? Down in premarket.
Definite positive!
Who bought/sold 1.2mm shares?
Correction on forgiveness. You don’t get to apply when you feel like it if you don’t want to pay interest on the outstanding monies prior to your forgiveness. Forgiveness had to have been applied for as interest started as of September 1.
News…. Sep. 27, 2021 8:12 AM ETNRx Pharmaceuticals, Inc. (NRXP)Relief Therapeutics Holding AG (RLFTF)By: Mamta Mayani, SA News Editor1 Comment
Variant mutation Covid-19 coronavirus. Showing genetic mutation
Bill Oxford/iStock via Getty Images
NRx Pharmaceuticals (NASDAQ:NRXP) perks up 3% premarket after announcing top line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19 who were treated with Zyesami (aviptadil).
A statistically significant difference in both survival and recovery from respiratory failure was reported at 28 days.
Top-line results show a statistically significant (P<.0001) 3-fold advantage in likelihood of being alive at one year post treatment (60% vs. 20%) among those treated with Zyesami, in addition to standard of care, compared to those who received the standard of care alone.
These findings are soon to be published in a peer-reviewed journal.
Zyesami remains under FDA review for emergency use authorization in patients suffering critical COVID-19 with respiratory failure.
Zyesami (aviptadil) is being developed in partnership with Relief Therapeutics (OTCQB:RLFTF).
Last month, NRXP reported positive Zyesami results in patients with respiratory distress due to COVID-19.
Now Read: IQVIA partners with NRX Pharma to support regulatory pathway for COVID-19 therapy
1 Comment
Share
Comment
Get alerts on
NRXP - NRx Pharmaceuticals, Inc.
Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF
Source: InvestorsHub NewsWire
TORONTO, Sept. 21, 2021 -- InvestorsHub NewsWire -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today that AdvisorShares® Investments LLC ("AdvisorShares"), a leading sponsor of actively managed exchange-traded funds (ETFs) has included Revive Therapeutics in the inaugural launch of its AdvisorShares Psychedelics ETF ("PSIL").
PSIL invests in the emerging psychedelic drugs sector, offering exposure to biotechnology, pharmaceutical, and life sciences companies leading the way in this nascent industry. The ETF at launch includes 16 publicly listed companies offering investors exposure to companies who are leading the way in the emerging psychedelics space.
"We are pleased to be included in the inaugural launch of the PSIL ETF as it provides further validation of our pharmaceutical psychedelics strategy in pursuing novel uses, formulations and delivery forms of psilocybin for the treatment of mental health and neurological conditions," said Michael Frank, CEO of the Company.
PSIL commenced trading on September 16, 2021, debuting on the New York Stock Exchange under ticker symbol (NYSE: PSIL). The holdings of PSIL and its current portfolio weights are regularly updated and available at https://advisorshares.com/etfs/psil/.
About Revive Therapeutics Ltd.
Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive's cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Come on! WTF
Awesome…thank you Blue! I haven’t posted much over last several months but I’m very long in RVVTF. Hope to hear good news soon.
Gig ‘Em horns!! God Bless Texas
That is an outstanding reply CW. Thank you for submitting it.